RMD insider notice: up to 2,000 shares to be sold on NYSE
Rhea-AI Filing Summary
ResMed (RMD): Form 144 filed for a planned sale of up to 2,000 common shares. The notice lists an aggregate market value of $504,100, with sales expected on or about 11/12/2025 on the NYSE through Merrill Lynch (2049 Century Park East, Ste 1200, Los Angeles, CA 90067). This is a resale by a security holder under Rule 144; proceeds would go to the seller, not the company.
The filing shows the issuer had 44,448,959 shares outstanding. The shares to be sold were acquired on 09/01/2014 via a stock option for cash, in the amount of 2,000 shares, from Peter C Farrell.
Positive
- None.
Negative
- None.